Patricia Marques Mendes

Dr. Patricia Marques Mendes


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2026 in Muscles
Verified
Journal Article
Open access
PDF file
FAFelipe Azeka
Felipe Azeka
PSPaulo de Lima Serrano
Paulo de Lima Serrano
DSDaniel Delgado Seneor
Daniel Delgado Seneor
SCSophia Calegaretti
Sophia Calegaretti
MPMateus Medeiros Pinheiro
Mateus Medeiros Pinheiro
Paulo Victor Sgobbi SouzaPaulo Victor Sgobbi Souza
Paulo Victor Sgobbi Souza
Congenital Myasthenic Syndrome represents a complex and heterogeneous group of inherited neuromuscular disorders, which result from variants in genes involved in different pathophysiological mechanisms related to the neuromuscular junction. LRP4 (Low-density lipoprotein receptor-related protein 4) represents one of the most important proteins involved in this complex signaling pathway, acting in a complex with agrin and Muscle Skeletal Receptor Tyrosine Kinase (MuSK) proteins. LRP4 became known to most neurologists due to the description of anti-LRP4 antibody-related Myasthenia Gravis. There are, however, different neurological and neuromuscular disorders that result from pathogenic variants in LRP4 gene, especially a rare and potentially treatable Congenital Myasthenic Syndrome. The authors performed a detailed narrative review, including descriptions of the main pathophysiological, clinical, and therapeutic aspects of LRP4-related Congenital Myasthenic Syndromes.

9 June 2026 in Genes
Verified
Journal Article
Open access
PDF file
DSDaniel Seneor
Daniel Seneor
JBJoão Paulo Barile
João Paulo Barile
PMPatricia Marques Mendes
Patricia Marques Mendes
MOMarco Orsini
Marco Orsini
ESEduardo Mendonça Werneck da Silva
Eduardo Mendonça Werneck da Silva
Paulo Victor Sgobbi SouzaPaulo Victor Sgobbi Souza
Paulo Victor Sgobbi Souza
Arthrogryposis multiplex congenita (AMC) is a diverse group of conditions characterized by multiple joint contractures. Although individually rare, these disorders are estimated to affect 1 in 3000–5000 live births. Their common pathophysiological mechanism is fetal akinesia, a sustained reduction of fetal movement that may arise from intrinsic disturbances—such as central nervous system malformations, motor neuronopathies, neuropathies, neuromuscular junction defects, congenital myopathies, muscular dystrophies, or metabolic diseases—or from extrinsic factors including uterine constraint, maternal illness, infections, or toxic exposures. Reduced fetal motion leads to relatively uniform clinical manifestations, known as the fetal akinesia deformation sequence (FADS), which is characterized by craniofacial anomalies, pulmonary hypoplasia, growth restriction, and contractures. Currently, AMC is classified by clinical features, such as distal arthrogryposis or lethal congenital contracture syndromes. However, advances in molecular genetics have shown wide variability among conditions classified into the same category. Prognosis is widely variable, ranging from lethal perinatal forms to non-progressive mild conditions. This review discusses AMC etiologies from a topographic standpoint, considering the different levels of the motor system involved, by combining current clinical, genetic, and pathophysiological information.